STOCK TITAN

Abbvie Stock Price, News & Analysis

ABBV NYSE

Company Description

Corporate Overview

AbbVie Inc. is a globally recognized pharmaceutical company that focuses on discovering and delivering innovative medicines to address serious health issues. Spun off from Abbott in 2013, the company has since built a reputation for excellence in research and development, driving breakthroughs in immunology, oncology, neuroscience, and beyond. As one of the largest biomedical firms by revenue, AbbVie operates with a clear commitment to improving patient outcomes and advancing therapeutic innovation.

Business Model and Core Operations

At its core, AbbVie develops, manufactures, and commercializes pharmaceuticals that address complex medical conditions including autoimmune disorders, cancers, and neurological diseases. The company's revenue originates primarily from the sales of several blockbuster drugs and its diversified portfolio of therapies, which has been further enhanced by strategic acquisitions. By investing heavily in R&D, AbbVie continually refines its drug development process, contributing to a robust pipeline of treatments that cover multiple therapeutic areas.

Therapeutic Areas and Strategic Focus

AbbVie's operations span several critical therapeutic areas. In immunology, the company has established itself by offering treatments that address autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Its portfolio in oncology further underscores its commitment to tackling various cancers through targeted therapies and antibody-drug conjugates. Additionally, the company engages in research within neuroscience and eye-care sectors, augmenting its comprehensive approach to addressing life-changing medical challenges.

Research, Innovation, and Competitive Positioning

Central to AbbVie’s success is its focus on advanced R&D and strategic collaborations. The company leverages cutting-edge technologies and innovative platforms to explore new treatment modalities, ranging from bispecific antibodies to next-generation small molecule therapeutics and gene therapies. Its ability to integrate novel research methods with established clinical expertise has allowed AbbVie to distinguish itself in a competitive global market. Through strategic partnerships and licensing arrangements with other biotech innovators, AbbVie continually evolves its product offerings and expands its influence across multiple segments within the pharmaceutical industry.

Market Significance and Global Impact

With a diversified portfolio and a solid foundation in drug discovery and development, AbbVie has carved out a significant market niche. The company’s emphasis on addressing unmet medical needs has earned it a formidable competitive edge in the global pharmaceutical landscape. Continuous developments in research and collaboration have further consolidated its position among the world's leading drug manufacturers. AbbVie's operations not only impact patients by providing life-changing therapies but also contribute to the broader healthcare ecosystem through its commitment to innovation and excellence.

Operational Excellence and Commitment to Quality

AbbVie maintains a high standard of operational excellence by adhering to rigorous protocols in clinical research and product development. Quality, safety, and regulatory compliance are pillars of its corporate philosophy, ensuring that each therapy produced meets the highest industry standards. This steadfast commitment builds trust and reinforces the company's reputation for expertise, authoritativeness, and reliability.

Investor Insights

For investors, AbbVie represents a blend of innovative R&D capabilities and a diversified revenue stream. Its strategic investments in cutting-edge therapies and collaborative efforts provide a transparent view of its business model, making it a compelling subject for comprehensive investment research. The company’s detailed approach to overcoming industry challenges through technological advancements and operational discipline is reflected in its sustained performance and market recognition.

This overview provides an in-depth look at AbbVie’s robust presence within the pharmaceutical sector, emphasizing its strategic focus on delivering transformational therapies. The structure of the content is designed to offer clarity for both new and seasoned investors seeking to understand AbbVie’s business model, operations, and market significance.

Stock Performance

$181.00
+2.23%
+3.95
Last updated: April 24, 2025 at 16:20
11.19 %
Performance 1 year
$312.8B
Market Cap
1.8B
Shares outstanding

SEC Filings

No SEC filings available for Abbvie.

Financial Highlights

$14,460,000,000
Revenue (TTM)
$1,564,000,000
Net Income (TTM)
$0.88
Diluted EPS (TTM)
$5,447,000,000
Operating Cash Flow
10.82%
Net Profit Margin
26.49%
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Abbvie (ABBV)?

The current stock price of Abbvie (ABBV) is $176.95 as of April 23, 2025.

What is the market cap of Abbvie (ABBV)?

The market cap of Abbvie (ABBV) is approximately 312.8B.

What is the revenue (TTM) of Abbvie (ABBV) stock?

The trailing twelve months (TTM) revenue of Abbvie (ABBV) is $14,460,000,000.

What is the net income of Abbvie (ABBV)?

The trailing twelve months (TTM) net income of Abbvie (ABBV) is $1,564,000,000.

What is the earnings per share (EPS) of Abbvie (ABBV)?

The diluted earnings per share (EPS) of Abbvie (ABBV) is $0.88 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Abbvie (ABBV)?

The operating cash flow of Abbvie (ABBV) is $5,447,000,000.

What is the profit margin of Abbvie (ABBV)?

The net profit margin of Abbvie (ABBV) is 10.82%.

What is the operating margin of Abbvie (ABBV)?

The operating profit margin of Abbvie (ABBV) is 26.49%.

What is the gross margin of Abbvie (ABBV)?

The gross profit margin of Abbvie (ABBV) is 70.87%.

What is the current ratio of Abbvie (ABBV)?

The current ratio of Abbvie (ABBV) is 0.65, indicating the company's ability to pay short-term obligations.

What is the gross profit of Abbvie (ABBV)?

The gross profit of Abbvie (ABBV) is $10,248,000,000 on a trailing twelve months (TTM) basis.

What is the operating income of Abbvie (ABBV)?

The operating income of Abbvie (ABBV) is $3,831,000,000.

What is AbbVie Inc.?

AbbVie Inc. is a major global pharmaceutical company specializing in developing and commercializing innovative therapies across multiple therapeutic areas.

Which therapeutic areas does AbbVie focus on?

AbbVie focuses on immunology, oncology, neuroscience, and eye care, among other areas, addressing complex conditions such as autoimmune diseases and various cancers.

How does AbbVie generate revenue?

Revenue is generated through the commercialization of blockbuster drugs, a diversified product portfolio, and strategic acquisitions that enhance its market presence.

What differentiates AbbVie in the pharmaceutical industry?

AbbVie's commitment to advanced research and innovation, combined with strategic collaborations and a robust R&D pipeline, sets it apart from competitors.

How does AbbVie approach research and development?

The company invests heavily in R&D and leverages cutting-edge technologies and partnerships to develop novel therapies that address significant unmet medical needs.

What are some key products or portfolios of AbbVie?

While AbbVie is known for its flagship products in immunology and oncology, its portfolio spans a broad range of treatments that cover several disease areas.

How does AbbVie maintain quality and compliance?

AbbVie adheres to stringent quality and regulatory standards throughout its research, development, and manufacturing processes to ensure safety and efficacy.

What makes AbbVie a reliable choice for investors?

Its long-established expertise, diversified revenue streams, and strategic R&D initiatives highlight AbbVie's resilience and strong positioning within the global pharmaceutical market.